Parallelism, Chromogenic Methods, and Interference

Before a factor activity is interpreted, the patient's serial dilutions should track parallel to the calibration curve. A parallel result means the patient's dilution curve has the same shape as the reference curve, just offset by the activity level, which is the assumption the one-stage assay depends on. A nonparallel result, where activity rises or falls in a way that does not track the calibrator, can signal an inhibitor or an activated sample rather than a stable factor level. A nonparallel result should trigger investigation and repeat testing at a different dilution, not averaging across dilutions to produce a single number.

A chromogenic FVIII (or FIX) assay works differently. Instead of timing a clot, it measures factor-dependent generation of activated factor X (FXa), detected by cleavage of a chromogenic substrate and read photometrically against a standard curve. Because it does not depend on the same phospholipid-dependent clotting reaction as the one-stage assay, a chromogenic FVIII result can help resolve a low one-stage FVIII result when lupus anticoagulant (LA) is suspected, since chromogenic assays are usually insensitive to that interference. LA can also lower apparent intrinsic factor activities on clot-based assays generally, and it can coexist with a true FVIII problem, so a low one-stage result with LA present is not automatically explained away.

Several other interferences deserve a name check at this stage. Recent heparin can materially depress a one-stage FVIII result while leaving a chromogenic FVIII result largely unaffected, based on a comparison study of methods. DOACs can cause false factor activity results in clot-based assays, with the direction and size of the effect depending on the specific drug, reagent, and assay design; rivaroxaban in particular has produced false-low FVIII and FIX activities in a multicenter assessment. Emicizumab, a bispecific antibody therapy, shortens aPTT-based FVIII assays and clot-based inhibitor studies, so a bovine-reagent chromogenic FVIII method is required for FVIII inhibitor measurement when a patient is on emicizumab.

FVIII inhibitors themselves are frequently time- and temperature-dependent, which is why the immediate and roughly 2-hour, 37 C incubated mix results are compared rather than relying on either alone. Multiple factor deficiencies, prolonging both PT and aPTT together, point toward a different differential: reduced hepatic synthesis or vitamin K deficiency rather than a single specific inhibitor. A broad multi-factor deficiency pattern does not, by itself, support a single-factor inhibitor conclusion.

Before trusting a low FVIII result, check parallelism, check the medication history, and consider whether a chromogenic assay would separate a true deficiency from an assay artifact.